Therapeutic Silencing of KRAS using Systemically Delivered siRNAs

Despite being amongst the most common oncogenes in human cancer, to date there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS mutated cancer models. We identified KRAS siRNA sequences with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Pecot, Chad V., Wu, Sherry Y., Bellister, Seth, Filant, Justyna, Rupaimoole, Rajesha, Hisamatsu, Takeshi, Bhattacharya, Rajat, Maharaj, Anshumaan, Azam, Salma, Rodriguez-Aguayo, Cristian, Nagaraja, Archana S., Morelli, Maria Pia, Gharpure, Kshipra M., Waugh, Trent A., Gonzalez-Villasana, Vianey, Zand, Behrouz, Dalton, Heather J., Kopetz, Scott, Lopez-Berestein, Gabriel, Ellis, Lee M., Sood, Anil K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4416486/
https://ncbi.nlm.nih.gov/pubmed/25281617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0074
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados